logo

Zogenix, Inc. (ZGNX)



Trade ZGNX now with
  Date
  Headline
9/23/2020 11:28:33 PM Zogenix Prices Offering Of $200 Mln Aggregate Principal Amount Of 2.75% Convertible Senior Notes Due 2027
9/21/2020 8:18:36 AM Zogenix Appoints Caroline Loewy, Mary Stutts And Denelle Waynick To Newly Created Seats On Board
6/25/2020 11:31:36 PM FDA Oks Zogenix's FINTEPLA To Treat Seizures Associated With Dravet Syndrome; Commercial Launch Planned For July 2020
6/12/2020 8:11:23 AM Zogenix Unveils New Resources For Dravet Syndrome Siblings
4/20/2020 8:13:11 AM Zogenix Appoints Shawnte Mitchell To Role Of EVP, General Counsel And Secretary
2/27/2020 10:47:57 AM Stock Alert: Zogenix Loses 14%
12/17/2019 7:41:25 PM Zogenix : FINTEPLA Shows Dose-dependent Reduction In Convulsive Seizure Frequency In Dravet Syndrome Patients
11/25/2019 8:05:23 AM Zogenix Reports FDA Acceptance For Filing Of NDA, Priority Review For FINTEPLA
10/7/2019 8:05:54 AM Zogenix Subsidiary, Modis Therapeutics, Presents Positive Top-line Results From Pivotal Phase 2 RETRO Study
9/26/2019 7:16:08 AM Zogenix Resubmits New Drug Application For FINTEPLA
9/9/2019 8:13:20 AM Zogenix Completes Acquisition Of Modis Therapeutics
8/26/2019 7:09:51 AM Zogenix To Acquire Modis Therapeutics